Radiotherapy for hidradenitis suppurativa that has not responded to other treatments
Tests radiation of one armpit in adults with hard-to-treat hidradenitis suppurativa.
Key facts
- Who runs it
- Thomas Jefferson University
- Where
- Cherry Hill and Philadelphia, United StatesSee the 2 sites
- Trial code
- Registry title
- Radiotherapy for Refractory Hidradenitis Suppurativa
- Status
- Recruiting
- People taking part
- 10 people, planned
- Started
- 1 May 2026
- Expected to end
- 1 Mar 2028
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Radiated axilla
- Record updated
- 15 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderate or severe hidradenitis suppurativa (HS) in both armpits. One armpit gets radiotherapy, the other keeps standard care.
- Age
- 18 years or older
- Sex
- Male or female
- Disease stage
- Moderate or severe HS (Hurley Stage II or III), affecting both armpits with about the same severity.
- Earlier treatment
- People already on HS creams or HS medicines for at least 1 month keep taking them. People who started a new whole-body HS treatment less than 1 month before joining cannot join. People who had radiotherapy as treatment before cannot join.
Main reasons for not taking part
- Pregnancy. Women who can become pregnant must use birth control and have a negative pregnancy test 7 days before the radiotherapy planning scan.
- Severe autoimmune diseases such as lupus, scleroderma or mixed connective tissue disease
- Poorly controlled diabetes, HIV, or hepatitis B or C
- Active cancer
- Sensitivity to light, past reactions to radiation, or any reason the radiation doctor says radiotherapy cannot be given
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Male or female subjects between the age of 18 or older with moderate or severe HS (Hurley Stage II or III) with bilateral axillary disease of approximately equivalent disease severity will be included
- Patients on topical and/or systemic HS medications for at least 1 month will continue maintenance treatment throughout the study period as per standard of care
- Patients willing and able to provide informed consent
Who cannot take part
- Pregnancy - Women of childbearing potential must use trial approved birth control and obtain a negative pregnancy test 7 days prior to radiotherapy CT simulation
- Prior therapeutic radiotherapy
- Contraindication to radiotherapy as determined by treating radiation oncologist
- Patients who began new systemic treatment for their HS <1 month prior to enrollment in trial
- History of photosensitivity disorders or prior radiation sensitization syndromes
- Any contraindication to radiotherapy as determined by the treating radiation oncologist
- Severe autoimmune conditions including lupus, scleroderma and mixed connective tissue disease
- Poorly controlled diabetes per physician discretion, HIV, Hepatitis B/C
- Active malignancy
Where in United States
- Jefferson Cherry Hill - Radiation OncologyCherry Hill, United StatesContact: Gregory Alexander, MDTaking people
- Thomas Jefferson UniversityPhiladelphia, United StatesContact: Sherry Yang, MDTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if high-dose radiotherapy can provide sustained disease relief in moderate to severe, treatment resistant Hidradenitis suppurativa patients; could include any of the following: any sex/gender, and those greater then 18 years old. The main question[s] it aims to answer are:
Read full original descriptionShow less
Outcome measure 1: Will radiotherapy change the number of inflammatory nodules, abscesses, and draining sinus tracts in the treated axilla compared with the untreated axilla? Outcome measure 2: Will radiotherapy positively change a patient's quality of life, pain levels and symptom burden?
Participants will receive radiotherapy to one axilla affected by hidradenitis suppurativa. The contralateral axilla will not receive radiotherapy and will continue receiving the standard treatment regimen.
Participants will...
* Attend a baseline dermatology skin evaluation, complete multiple surveys and an optional participation in a biopsy * Attend multiple radiation sessions over 5 weeks * Attend 2 follow up visits with dermatology for skin evaluation, complete follow up surveys, and an optional biopsy.
The 2 groups in the trial
- Radiation axillaTreatment being tested
Participants will receive radiotherapy to one axilla affected by hidradenitis suppurativa.
Treatment: Radiated axilla
- Non-radiated AxillaNo study treatment, for comparison
The contralateral axilla will not receive radiotherapy and will continue on the current standard of care.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Radiotherapy for Treatment of Recalcitrant Hidradenitis Suppurativa (RADIANT-SUPPoRT)
- Plain-language title
- Radiotherapy for hidradenitis suppurativa that has not responded to other treatmentsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 15 May 2026